• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

手术标本中的癌前病变不会恶化接受胰腺腺癌手术患者的预后:PRODIGE 24-CCTG PA 6试验的事后分析

Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial.

作者信息

Legrand Théo, Salleron Julia, Conroy Thierry, Marchal Frédéric, Thomas Jacques, Monard Laure, Biagi James Jim, Lambert Aurélien

机构信息

Department of Medical Oncology, Institut de Cancérologie de Lorraine, 54500 Vandœuvre-lès-Nancy, France.

Biostatistic Unit, Institut de Cancérologie de Lorraine, 54500 Vandœuvre-lès-Nancy, France.

出版信息

Cancers (Basel). 2022 Aug 16;14(16):3945. doi: 10.3390/cancers14163945.

DOI:10.3390/cancers14163945
PMID:36010938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9406034/
Abstract

OBJECTIVE

The prognosis of pancreatic cancer after curative surgery is burdened by frequent recurrence. The aim of this study was to evaluate the impact of dysplasia in the surgical specimen on disease-free survival (DFS).

METHODS

A post-hoc analysis of the phase III PRODIGE 24-CCTG PA 6 trial was performed. From April 2012 to October 2016, 493 patients were included in the primary study. Assessment for dysplasia in the surgical specimens was secondarily performed. Dysplasia was defined based on presence and grade of three most common pre-malignant lesions (intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN) and pancreatic intraepithelial neoplasia (PanIN). The primary endpoint was DFS validated through multivariate analysis.

RESULTS

Two hundred twenty-six patients (45.9%) had a preneoplastic lesion. PanIN lesions were found in 193 patients (39.2%), including 100 high-grade lesions (20.6%); 43 patients had IPMN lesions (8.7%), including high-grade lesions in 32 (6.5%). Three MCN were described (0.6%). In bivariate analysis, the presence of dysplasia was not associated with poorer DFS (HR = 0.82, 95% CI [0.66; 1.03]). In multivariate analysis, risk factors for poorer DFS were poorly differentiated/undifferentiated tumor, N1 status, R1 surgical margins and perineural invasion.

CONCLUSIONS

The presence of dysplasia in the surgical specimen after pancreatic cancer surgery does not worsen DFS.

摘要

目的

根治性手术后胰腺癌的预后常因频繁复发而受到影响。本研究旨在评估手术标本中的发育异常对无病生存期(DFS)的影响。

方法

对III期PRODIGE 24-CCTG PA 6试验进行事后分析。2012年4月至2016年10月,493例患者纳入了该初步研究。其次对手术标本中的发育异常进行评估。发育异常是根据三种最常见的癌前病变(导管内乳头状黏液性肿瘤(IPMN)、黏液性囊性肿瘤(MCN)和胰腺上皮内瘤变(PanIN))的存在情况和分级来定义的。主要终点是通过多变量分析验证的DFS。

结果

226例患者(45.9%)有癌前病变。193例患者(39.2%)发现有PanIN病变,其中100例为高级别病变(20.6%);43例患者有IPMN病变(8.7%),其中32例为高级别病变(6.5%)。描述了3例MCN(0.6%)。在二元分析中,发育异常的存在与较差的DFS无关(HR = 0.82,95%CI [0.66;1.03])。在多变量分析中,DFS较差的危险因素是低分化/未分化肿瘤、N1状态、R1手术切缘和神经周围侵犯。

结论

胰腺癌手术后手术标本中存在发育异常并不会使DFS恶化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6791/9406034/97b19ccd0052/cancers-14-03945-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6791/9406034/97b19ccd0052/cancers-14-03945-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6791/9406034/97b19ccd0052/cancers-14-03945-g001.jpg

相似文献

1
Preneoplastic Lesions in Surgical Specimens Do Not Worsen the Prognosis of Patients Who Underwent Surgery for Pancreatic Adenocarcinoma: Post-Hoc Analysis of the PRODIGE 24-CCTG PA 6 Trial.手术标本中的癌前病变不会恶化接受胰腺腺癌手术患者的预后:PRODIGE 24-CCTG PA 6试验的事后分析
Cancers (Basel). 2022 Aug 16;14(16):3945. doi: 10.3390/cancers14163945.
2
Precursor lesions of pancreatic cancer.胰腺癌的癌前病变。
Gut Liver. 2008 Dec;2(3):137-54. doi: 10.5009/gnl.2008.2.3.137. Epub 2008 Dec 31.
3
Pancreatic intraepithelial neoplasia in patients with intraductal papillary mucinous neoplasms: the interest of endoscopic ultrasonography.胰腺内上皮内瘤变患者的导管内乳头状黏液性肿瘤:内镜超声检查的意义。
Pancreas. 2013 Nov;42(8):1262-6. doi: 10.1097/01.mpa.0000437639.38383.41.
4
Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.丝氨酸蛋白酶抑制剂Kazal 1型和表皮生长因子受体在胰腺导管腺癌、导管内乳头状黏液性肿瘤及胰腺上皮内瘤变中均有表达。
J Hepatobiliary Pancreat Sci. 2013 Aug;20(6):620-7. doi: 10.1007/s00534-012-0587-6.
5
The pathological features and prognoses of intraductal papillary mucinous neoplasm and mucinous cystic neoplasm after surgical resection: a single institution series.术后切除的导管内乳头状黏液性肿瘤和黏液性囊腺瘤的病理特征和预后:单中心系列研究。
World J Surg Oncol. 2020 Nov 4;18(1):287. doi: 10.1186/s12957-020-02063-8.
6
A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.一项关于胰腺分支导管内乳头状黏液性肿瘤手术切除后复发的大型多中心研究。
Minerva Gastroenterol Dietol. 2017 Mar;63(1):50-54. doi: 10.23736/S1121-421X.16.02341-2. Epub 2016 Nov 8.
7
hsa-miR-96 and hsa-miR-217 Expression Down-Regulates with Increasing Dysplasia in Pancreatic Intraepithelial Neoplasias and Intraductal Papillary Mucinous Neoplasms.在胰腺上皮内瘤变和导管内乳头状黏液性肿瘤中,随着发育异常程度增加,hsa-miR-96和hsa-miR-217的表达下调。
Int J Med Sci. 2017 Apr 8;14(5):412-418. doi: 10.7150/ijms.18641. eCollection 2017.
8
Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.导管内乳头状黏液性肿瘤及导管内乳头状黏液性肿瘤衍生的胰腺导管腺癌的分子机制
J Hepatobiliary Pancreat Sci. 2015 Jul;22(7):519-23. doi: 10.1002/jhbp.246. Epub 2015 Apr 21.
9
High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia.高级别胰腺上皮内瘤变:在胰腺肿瘤中的患病率及意义
Hepatobiliary Pancreat Dis Int. 2017 Apr;16(2):202-208. doi: 10.1016/s1499-3872(16)60186-8.
10
[Neoplastic intraepithelial lesions of pancreatic ducts: new entities].[胰腺导管的肿瘤性上皮内病变:新实体]
Ann Pathol. 2002 Oct;22(5):357-66.

引用本文的文献

1
Longitudinal Pancreatojejunostomy for Pancreaticodigestive Reconstruction in the Resection of Pancreatic Head Malignancy with Chronic Pancreatitis: A Case Report.用于胰头恶性肿瘤合并慢性胰腺炎切除术中胰消化重建的纵向胰空肠吻合术:一例报告
Surg Case Rep. 2025;11(1). doi: 10.70352/scrj.cr.24-0015. Epub 2025 Mar 4.
2
Lymphocyte-to-Monocyte Ratio Predicts Survival for Intraductal Papillary Mucinous Neoplasm with Associated Invasive Carcinoma of the Pancreas: Results from a High-Volume Center.淋巴细胞与单核细胞比值可预测胰腺导管内乳头状黏液性肿瘤伴发浸润性癌的生存情况:来自大容量中心的研究结果。
Dig Surg. 2024;41(3):111-121. doi: 10.1159/000540181. Epub 2024 Jul 18.
3

本文引用的文献

1
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
2
Tumor Microenvironment in Pancreatic Intraepithelial Neoplasia.胰腺上皮内瘤变中的肿瘤微环境
Cancers (Basel). 2021 Dec 8;13(24):6188. doi: 10.3390/cancers13246188.
3
IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.胰管内乳头状黏液性肿瘤相关胰腺癌:生存、预后分期和辅助化疗的影响。
Residual biliary intraepithelial neoplasia without malignant transformation at resection margin for perihilar cholangiocarcinoma does not require expanded resection: a dual center retrospective study.
肝门周围胆管癌切缘残留无恶性转化的胆管上皮内瘤变不需要扩大切除:一项双中心回顾性研究。
World J Surg Oncol. 2024 Jun 21;22(1):161. doi: 10.1186/s12957-024-03395-5.
4
Artificial intelligence as a noninvasive tool for pancreatic cancer prediction and diagnosis.人工智能作为一种非侵入性的胰腺癌预测和诊断工具。
World J Gastroenterol. 2023 Mar 28;29(12):1811-1823. doi: 10.3748/wjg.v29.i12.1811.
Eur J Surg Oncol. 2022 Jun;48(6):1309-1320. doi: 10.1016/j.ejso.2021.12.009. Epub 2021 Dec 11.
4
Pancreatic Cystic Lesions and Malignancy: Assessment, Guidelines, and the Field Defect.胰腺囊性病变与恶性肿瘤:评估、指南及领域缺陷。
Radiographics. 2022 Jan-Feb;42(1):87-105. doi: 10.1148/rg.210056. Epub 2021 Dec 2.
5
Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival.胰腺导管腺癌和浸润性导管内乳头状黏液性肿瘤:不同的总生存预后因素。
Dig Liver Dis. 2022 Jun;54(6):826-833. doi: 10.1016/j.dld.2021.06.006. Epub 2021 Jul 1.
6
Estimated Projection of US Cancer Incidence and Death to 2040.预估 2040 年美国癌症发病与死亡人数。
JAMA Netw Open. 2021 Apr 1;4(4):e214708. doi: 10.1001/jamanetworkopen.2021.4708.
7
Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment.淋巴结比率是 R0 切除和辅助治疗胰腺癌的有价值的预测指标。
BMC Cancer. 2019 Oct 15;19(1):952. doi: 10.1186/s12885-019-6193-0.
8
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.胰腺导管腺癌切除术后复发模式:ESPAC-4 随机辅助化疗试验的二次分析。
JAMA Surg. 2019 Nov 1;154(11):1038-1048. doi: 10.1001/jamasurg.2019.3337.
9
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
10
European evidence-based guidelines on pancreatic cystic neoplasms.欧洲胰腺囊性肿瘤循证临床实践指南。
Gut. 2018 May;67(5):789-804. doi: 10.1136/gutjnl-2018-316027. Epub 2018 Mar 24.